view페이지

임상1상 용량 증대 - 4번째 용량 시험

Sep 09, 2015EVENTSHit 978

The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.

Attachments
Previous thumbnail test
Next 메드팩토, 3번째 글로벌 공동 임상… 프레드 허친슨과 운영 계약